ArticleTrials2021

Clinical effectiveness and safety of baricitinib for the treatment of juvenile idiopathic arthritis-associated uveitis or chronic anterior antinuclear antibody-positive uveitis: study protocol for an open-label, adalimumab active-controlled phase 3 clinical trial (JUVE-BRIGHT).

Athimalaipet V Ramanan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.